Concierge gives you timely BUY and SELL alerts on ASX-listed stocks
Upgrade your Membership
Save $$$
Special Report on Cyclopharm (ASX:CYC): FDA approval is last piece of the puzzle
Marc Kennis, March 1, 2022
Cyclopharm
Cyclopharm’s (ASX:CYC) core radiopharmaceutical product, Technegas, is used in functional lung ventilation imaging, particularly for the diagnosis of pulmonary embolism (PE). CYC is already selling in 60 countries around the world, but US FDA approval would open up the vast US market.
CYC is on of Marc & Stuart’s Top Picks. You can read the full report below!
Stay up-to-date on ASX-listed Life Sciences stocks!
Make sure you subscribe to Stocks Down Under today
No credit card needed and the trial expires automatically.
Blog Categories
Recent Posts
Should I invest in metal exchanges rather than in resources stocks?
If investing in resources stocks (particularly junior explorers) is too risky, another option is investing in metal exchanges. But is…
Leo Lithium (ASX:LLL): Here’s why it was the best ASX lithium stock and why it isn’t anymore
Investors have been excited about Leo Lithium (ASX:LLL) over the past year and so have we! We thought this was…
Here are the 5 Top investing mistakes and how to avoid them
We recap the 5 top investing mistakes that investors make. These mistakes are not the only ones investors make, but…